During the forecast period, the remicade biosimilar market is expected to develop at a CAGR of 35.9%. In 2022, the market is currently valued at US$ 2212.86 million. The value of the remicade biosimilar market is expected to reach US$ 47,549.77 million by 2032. Biosimilars are biological products that are highly similar to an already FDA-approved medicine, known as the reference biological...